GDF2 and hepatocellular carcinoma: To further understand the role of BMP9‐ID1 signaling in the regulation of HCC‐CSCs, we assessed the effect of BMP receptor inhibitors in comparison with a potent TGFβ receptor I inhibitor galunisertib, which is currently being used in a clinical trial for advanced HCC [23].